Cynthia E. Herzog, MD
Department of Pediatrics, Division of Pediatrics
Present Title & Affiliation
Primary Appointment
Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1985 | University of Texas Medical Branch, Galveston, TX, USA, MD, Medicine |
| 1979 | Rice University, Houston, TX, USA, BA, Biochemistry |
Postgraduate Training
| 2004-2005 | Faculty Leadership Training, M. D. Anderson Cancer Center, Houston, TX |
| 1991-1992 | Senior Assistant Surgeon, National Cancer Institute, Bethesda, MD |
| 1988-1991 | Fellow in Pediatric Hematology-Oncology, National Cancer Institute, Bethesda, MD |
| 1985-1988 | Pediatric Residency, Children's Medical Center, Dallas, TX |
Board Certifications
| 1992 | The American Board of Pediatrics, Hematology/Oncology, Sub-Board of Pediatrics |
Experience & Service
Academic Appointments
Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2001 - 2008
Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1995 - 2001
Faculty Associate, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1992 - 1995
Administrative Appointments/Responsibilities
Center Medical Director- Child and Adolescent Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2019
Section Chief, Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, 2013 - 2015
Medical Director, Department of Clinical Research Department, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2013
Other Appointments/Responsibilities
Deputy Director, POETIC Clinical Program, New York, NY, 2014 - Present
Chair, POETIC Performance and Compliance Committee, New York, NY, 2013 - Present
Board of Director, POETIC Foundation, New York, NY, 2013 - Present
Coordinating Committee Member, The Retinoblastoma Center of Houston, Houston, TX, 2009 - Present
Advisory Board, Ronald MacDonald House, Houston, TX, 2001 - 2003
Physician Auditor, Office of Protocol Research Quality Assurance, Houston, 1998 - 1999
Honors & Awards
| 2005 | The Best Doctors in America |
| 2003 | Multi Year Appointment Award |
| 2001 | The Best Doctors in America |
| 1998 | The Best Doctors in America |
Selected Publications
Peer-Reviewed Articles
- Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog C, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JA. Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res 24(19):4865-4873, 2018. e-Pub 2018. PMID: 29871905.
- Manley PE, Trippett T, Smith AA, Macy ME, Leary SES, Boklan J, Cohen KJ, Goldman S, Kilburn LB, Dhall G, Devin J, Herzog C, Partap S, Fauchet F, Badreddine E, Bernard JP, Chi SN. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer 65(9):e27217, 2018. e-Pub 2018. PMID: 29750396.
- Hayes-Jordan AA, Coakley BA, Green HL, Xiao L, Fournier KF, Herzog CE, Ludwig JA, McAleer MF, Anderson PM, Huh WW. Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial. Ann Surg Oncol 25(4):872-877, 2018. e-Pub 2018. PMID: 29383611.
- Tarek N, Hayes-Jordan A, Salvador L, McAleer MF, Herzog CE, Huh WW. Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen. Pediatr Blood Cancer 65(1), 2018. e-Pub 2017. PMID: 28941151.
- Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Pappo A. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer 86:358-363, 2017. e-Pub 2017. PMID: 29100190.
- Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
- Amram AL, Rico G, Kim JW, Chintagumpala M, Herzog CE, Gombos DS, Chévez-Barrios P. Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation. Ophthalmology 124(10):1540-1547, 2017. e-Pub 2017. PMID: 28528011.
- Kumar R, Vu L, Madewell JE, Herzog CE, Bird JE. Glomangiomatosis of the sciatic nerve: a case report and review of the literature. Skeletal Radiol 46(6):807-815, 2017. e-Pub 2017. PMID: 28303299.
- Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24):39254-39267, 2017. PMID: 28424409.
- Huh WW, Daw NC, Herzog CE, Munsell MF, McAleer MF, Lewis VO. Ewing sarcoma family of tumors in children younger than 10 years of age. Pediatr Blood Cancer 64(4), 2017. e-Pub 2016. PMID: 27696711.
Abstracts
- Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Huh W, Anderson P, Pollock R, Lev D, Qiao W, McAleer MF, Benjamin R, Patel S, Herzog C, Daw N, Feig B, Lazar AJ, Hayes-Jordan A, Ludwig JA. Improved 3 and 5 Year Survival with Multimodality Treatment of Desmoplastic Small Round Cell Tumor. CTOS Rome, Italy, 2018.
- Groisberg R, Roszik J, Sen S, Conley AP, Lazar AJ, Hong DS, Naing A, Herzog C, Somaiah N, Zarzour MA, Patel S, Subbiah V. Treatment Patterns of Alveolar Soft Part Sarcoma Patients and Response to Multiple Experimental Therapies. CTOS Rome, Italy,, 2018.
- Yen C, Santiago F, Rad MG, Chévez-Barrios P, Herzog C, Kan P, Chintagumpala M, Lin F, Gombos D, Chen S. Five Year Retrospective Review of Chemosurgery for Retinoblastoma: Significant TechniqueRelated Differences and Opportunity for Improving Outcomes. Society of NeuroInterventional Surgery, San Francisco, CA, 2018.
- Pappo A, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Geoerger B. Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV mlaginant melanoma (MEL). ASCO 2017, 2017.
Grant & Contract Support
| Title: | Research Into Visual Endpoints and RB Health Outcomes After Treatment: The Riverboat Consortium |
| Funding Source: | NIH |
| Role: | Co-Investigator |